Northwest Biotherapeutics, Inc. (BST:NBYB)
Germany
· Delayed Price · Currency is EUR 0.2200
+0.0100 (4.76%)
At close: Jul 3, 2025
Northwest Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 1.47 | 1.38 | 1.93 | 1.68 | 1.01 | 1.29 | Upgrade
| |
Revenue Growth (YoY) | 10.25% | -28.47% | 14.79% | 67.46% | -22.15% | -46.43% | Upgrade
|
Cost of Revenue | 35.3 | 34.89 | 27.73 | 35.51 | 20.31 | 33.64 | Upgrade
|
Gross Profit | -33.82 | -33.51 | -25.8 | -33.83 | -19.3 | -32.35 | Upgrade
|
Selling, General & Admin | 34.25 | 33 | 29.71 | 33.35 | 33.4 | 54.26 | Upgrade
|
Operating Expenses | 34.25 | 33 | 29.71 | 33.35 | 33.4 | 54.26 | Upgrade
|
Operating Income | -68.08 | -66.51 | -55.51 | -67.18 | -52.7 | -86.61 | Upgrade
|
Interest Expense | -7.85 | -7.77 | -5.24 | -6.07 | -5.01 | -8.54 | Upgrade
|
Currency Exchange Gain (Loss) | 1.02 | -1.55 | 2.01 | -3.3 | -1.7 | 2.26 | Upgrade
|
Other Non Operating Income (Expenses) | 0.8 | -0.44 | 3.57 | -25.79 | 238.7 | -435.35 | Upgrade
|
EBT Excluding Unusual Items | -74.11 | -76.27 | -55.18 | -102.34 | 179.29 | -528.24 | Upgrade
|
Other Unusual Items | -10.7 | -7.51 | -7.42 | -2.69 | -0.17 | -1.58 | Upgrade
|
Pretax Income | -84.81 | -83.78 | -62.6 | -105.03 | 179.13 | -529.82 | Upgrade
|
Net Income | -84.81 | -83.78 | -62.6 | -105.03 | 179.13 | -529.82 | Upgrade
|
Preferred Dividends & Other Adjustments | 1.11 | 1.41 | 1.77 | - | - | - | Upgrade
|
Net Income to Common | -85.92 | -85.19 | -64.37 | -105.03 | 179.13 | -529.82 | Upgrade
|
Shares Outstanding (Basic) | 1,285 | 1,242 | 1,119 | 1,016 | 874 | 725 | Upgrade
|
Shares Outstanding (Diluted) | 1,285 | 1,242 | 1,119 | 1,016 | 1,008 | 725 | Upgrade
|
Shares Change (YoY) | 11.99% | 10.99% | 10.17% | 0.79% | 38.99% | 28.53% | Upgrade
|
EPS (Basic) | -0.07 | -0.07 | -0.06 | -0.10 | 0.21 | -0.73 | Upgrade
|
EPS (Diluted) | -0.07 | -0.07 | -0.06 | -0.10 | -0.06 | -0.73 | Upgrade
|
Free Cash Flow | -54.9 | -58.03 | -57.07 | -55.68 | -44.31 | -38.7 | Upgrade
|
Free Cash Flow Per Share | -0.04 | -0.05 | -0.05 | -0.06 | -0.04 | -0.05 | Upgrade
|
Operating Margin | -4621.52% | -4812.45% | -2873.09% | -3991.74% | -5243.98% | -6708.37% | Upgrade
|
Profit Margin | -5832.99% | -6164.40% | -3331.94% | -6240.76% | 17823.48% | -41039.58% | Upgrade
|
Free Cash Flow Margin | -3726.88% | -4199.06% | -2954.14% | -3308.20% | -4409.35% | -2997.91% | Upgrade
|
EBITDA | -66.33 | -64.76 | -53.98 | -65.93 | -52.38 | -86.52 | Upgrade
|
D&A For EBITDA | 1.75 | 1.74 | 1.53 | 1.25 | 0.32 | 0.09 | Upgrade
|
EBIT | -68.08 | -66.51 | -55.51 | -67.18 | -52.7 | -86.61 | Upgrade
|
Revenue as Reported | 1.47 | 1.38 | 1.93 | 1.68 | 1.01 | 1.29 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.